| Literature DB >> 22690335 |
Gokhan Cipe1, Mahmut Muslumanoglu, Erkan Yardimci, Naim Memmi, Erhan Aysan.
Abstract
In the treatment of distal rectal cancer, abdominoperineal resection is traditionally performed. However, the recognition of shorter safe distal resection line, intersphincteric resection technique has given a chance of sphincter-saving surgery for patients with distal rectal cancer during last two decades and still is being performed as an alternative choice of abdominoperineal resection. The first aim of this study is to assess the morbidity, mortality, oncological, and functional outcomes of intersphincteric resection. The second aim is to compare outcomes of patients who underwent intersphincteric resection with the outcomes of patients who underwent abdominoperineal resection.Entities:
Year: 2012 PMID: 22690335 PMCID: PMC3368590 DOI: 10.1155/2012/581258
Source DB: PubMed Journal: Int J Surg Oncol ISSN: 2090-1402
Figure 1Type of ISR according to amount of excision of the internal anal sphincter. a: partial ISR, b: subtotal ISR, and c: total ISR.
Complications and mortality after ISR.
| Reference | Anastomotic leak (%) | Anastomotic stricture (%) | Fistula (%) | Pelvic sepsis (%) | Wound complications (%) | Bleeding (%) | Bowel obstruction (%) | Rectal mucosal prolapse (%) | Mortality (%) |
|---|---|---|---|---|---|---|---|---|---|
| Braun et al. [ | 10 | 3 | 0 | 0 | 8 | 0 | 3 | NR | 6 |
| Bannon et al. [ | 0.9 | 0.9 | 0.9 | 0.9 | 1.8 | 0.9 | 0.9 | 1.8 | 1.0 |
| Köhler et al. [ | 48 | 10 | 19 | 0 | 6 | 3 | 10 | NR | 0 |
| Kim et al. [ | 6.2 | 6.2 | 4.2 | NR | NR | NR | 8.3 | NR | NR |
| Tiret et al. [ | 11 | NR | NR | 3.8 | NR | 3.8 | NR | NR | 0 |
| Luna-pérez et al. [ | 9.4 | 6.25 | 6.25 | 9.3 | 6.25 | NR | 6.25 | NR | NR |
| Rullier et al. [ | 11 | 0 | 2 | 3 | 0 | 7 | 0 | NR | 0 |
| Schiessel et al. [ | NR | NR | 5.1 | NR | NR | 0.8 | NR | NR | 0.8 |
| Hohenberger et al. [ | NR | NR | NR | NR | NR | NR | NR | NR | 3 |
| Saito et al. [ | 10.1 | 0 | 1.3 | 4.4 | 0 | 1.3 | 0 | 1.3 | 0.4 |
| Chamlou et al. [ | 9 | 0 | 1 | 5 | 1 | 2 | 0 | NR | 0 |
| Dai et al. [ | NR | 8.7 | 8.7 | NR | NR | NR | NR | NR | 0 |
| Akasu et al. [ | 13.0 | NR | NR | NR | NR | NR | NR | NR | 0.8 |
| Akasu et al. [ | 13 | 0.8 | NR | NR | 6.6 | NR | 5 | 0.8 | 0.8 |
| Han et al. [ | 3 | 0 | 0 | 0 | 5 | 0 | 0 | NR | 0 |
| Krand et al. [ | 4 | 2 | 0 | 2 | 9 | 0 | 2 | NR | 0 |
| Saito et al. [ | NR | NR | NR | NR | NR | NR | NR | NR | 0 |
| Weiser et al. [ | 5 | 16 | 5 | 0 | 7 | 0 | 16 | NR | 0 |
| Yamada et al. [ | 4.7 | 8.4 | 0 | 0 | 3.7 | 0 | 8.4 | 3.7 | 0 |
| Han et al. [ | 1.6 | 2.5 | 0.6 | NR | NR | NR | NR | NR | NR |
| Park et al. [ | 6.2 | 1.3 | NR | NR | NR | NR | 2.5 | NR | 1.3 |
| Lim et al. [ | 1.8 | 6.3 | 0.9 | 2.7 | NR | NR | 4.5 | 1.8 | 0 |
| Bennis et al. [ | 7 | NR | NR | NR | NR | 1.6 | 2.69 | NR | 0.4 |
| Reshef et al. [ | NR | NR | NR | 2.9 | 4.5 | NR | NR | NR | 0.7 |
Oncologic results of ISR.
| Reference | Year |
| Median followup | Local recurrence | 5-year survival (overall) | 5-year survival (disease free) |
|---|---|---|---|---|---|---|
| Braun et al. [ | 1992 | 63 | 80 | 11 | 62 | NR |
| Marks et al. [ | 1993 | 52 | 50 | 14 | 85 | NR |
| Bannon et al. [ | 1995 | 109 | 40 | 11.0 | 87 | NR |
| Mohiuddin et al. [ | 1998 | 48 | 48 | 15 | 82 | NR |
| Köhler et al. [ | 2000 | 31 | 82 | 10 | 79 | NR |
| Kim et al. [ | 2001 | 48 | 26 | 4.1 | NR | NR |
| Tiret et al. [ | 2003 | 26 | 39 | 3.4 | NR | NR |
| Nakagoe et al. [ | 2004 | 184 | 47.4 | 9.5 | NR | 73.6 |
| Rullier et al. [ | 2005 | 92 | 40 | 2 | 81 | 70 |
| Yoo et al. [ | 2005 | 29 | 57 | 31 | 86.2 | 65.7 |
| Schiessel et al. [ | 2005 | 121 | 94 | 5.3 | 88 | NR |
| Hohenberger et al. [ | 2006 | 65 | 70 | 23 | NR | NR |
| Saito et al. [ | 2006 | 228 | 41 | 3.6 | 92 | 83 |
| Chamlou et al. [ | 2007 | 90 | 56 | 7 | 82 | 75 |
| Dai et al. [ | 2008 | 23 | 31.5 | 8.7 | NR | NR |
| Akasu et al. [ | 2008 | 120 | 42 | 6.7 | 91 | 77 |
| Krand et al. [ | 2009 | 47 | 68 | 2 | 85 | 82 |
| Han et al. [ | 2009 | 40 | 43 | 5 | 97 | 86 |
| Yamada et al. [ | 2009 | 107 | 41 | 2.5 | 92 | 87 |
| Weiser et al. [ | 2009 | 44 | 47 | 0 | 96 | 83 |
| Saito et al. [ | 2009 | 132 | 40 | 10.6 | 80 | 69 |
| Han et al. [ | 2010 | 310 | 84 | 11.6 | 66 | NR |
| Lim et al. [ | 2011 | 111 | 29.4 | 5.4 | NR | NR |
| Kuo et al. [ | 2011 | 162 | 55 | 7.7 | 83 | 76 |
| Reshef et al. [ | 2012 | 986 | 60 | 3 | 71 | 69 |
Functional results of ISR.
| Reference | Year |
| Anal manometry | Functional tool | Bowel movements per 24 hours | Complete incontinence (%) | Incontinence to flatus (%) | Faecal soiling (%) | Urgency (%) |
|---|---|---|---|---|---|---|---|---|---|
| Braun et al. [ | 1992 | 63 | No | Mayo clinic classification | 2.2 (1–3) | 75 | 17 | 15 | 22 |
| Köhler et al. [ | 2000 | 31 | Yes | General questionnaire | 3.3 (NR) | 30 | 11 | 63 | NR |
| Kim et al. [ | 2001 | 48 | No | Kirwan classification | 4.4 (3–6) | NR | NR | NR | NR |
| Tiret et al. [ | 2003 | 25 | No | NR | 2.5 (NR) | 50 | 23 | 27 | 19 |
| Schiessel et al. [ | 2005 | 121 | Yes | Williams and johnston classification | 2.2 (1–9) | 86.3 | NR | 13.7 | NR |
| Yoo et al. [ | 2005 | 17 | No | Cleveland clinic incontinence score | 5.0 (2–9) | NR | 17.6 | 41.2 | 58.8 |
| Saito et al. [ | 2006 | 228 | No | Jorge and wexner incontinence score and kirwan score | NR | 32.7 | 29.1 | 29.1 | NR |
| Chamlou et al. [ | 2007 | 90 | No | Jorge and wexner incontinence score | 2.3 (NR) | 41 | 25 | 59 | 19 |
| Yamada et al. [ | 2009 | 107 | No | Jorge and wexner incontinence score and Kirwan score | 3.7 (2–6) | 42.3 | NR | 27.9 | NR |
| Han et al. [ | 2009 | 40 | No | Kirwan classification | 2.7 (NR) | 43 | 29 | 29 | 31 |
| Krand et al. [ | 2009 | 47 | No | Kirwan classification | 2.3 (2–5) | 80 | 9 | 11 | 2 |
| Kuo et al. [ | 2011 | 22 | No | Wexner incontinence score | 4.7 (NR) | NR | NR | NR | 19 |
Comparison ISR versus APR in terms of morbidity and oncologic outcomes.
| References | No of patients | Overall morbidity | Local recurrence | Overall survival | Disease free survival | Median followup (months) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ISR % | APR % |
| ISR % | APR % |
| ISR % | APR % |
| ISR % | APR % |
| ISR % | APR % |
| ||
| Braun et al. [ | 65 | 77 | NR | 30 | NR | NR | 11 | 17 | NR | 62 | 53 | NR | NR | NR | NR | 79 |
| Kasper et al. [ | 85 | 81 | NR | NR | NR | NR | 8.7 | 17 | NR | 71 | 55 | NR | NR | NR | NR | 60 |
| Saito et al. [ | 132 | 70 | 0.18 | 30.3 | 28.6 | 0.30 | 10.6 | 15.7 | 0.29 | 80 | 61 | 0.03 | 69% | 63% | 0.714 | 48 |
| Weiser et al. [ | 44 | 63 | NR | 38.6 | 34.9 | NR | 0 | 9 | NR | 96 | 59 | NR | 83% | 47% | NR | 47 |
| Kuo et al. [ | 26 | 23 | NR | NR | NR | NR | 0 | 3.8 | NR | 83 | 46 | 0.006 | 76% | 42% | 0.029 | 55 |